Cytochrome P450-dependent eicosanoid production and crosstalk

Current Opinion in Lipidology

Volumn 22, Issue 5, 2011, Pages 403-409

  Fleming, Ingrid ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

epoxyeicosatrienoic acids; fish oil; pulmonary hypertension; vascular disease

Indexed keywords

ARACHIDONIC ACID; CYTOCHROME P450; FATTY ACID; HYDROLASE; ICOSANOID; SOLUBLE EPOXIDE HYDROLASE; UNCLASSIFIED DRUG;

ADIPOCYTE; ENZYME METABOLISM; HUMAN; HYPERTENSION; IN VIVO STUDY; LUNG; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; EICOSAPENTAENOIC ACID; EPOXIDE HYDROLASES; HUMANS; HYPERTENSION; VASCULAR DISEASES;

ANIMALIA; MUS;

EID: 80052757946     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32834a9790     Document Type: Review

References (51)

1. Campbell WB, Fleming I. Epoxyeicosatrienoic acids and endotheliumdependent responses. Pflü ger's Arch Eur J Pharmacol 2010; 459:881-895.
2. Khojasteh S, Prabhu S, Kenny J, et al. Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 2011; 36:1-16.
3. Michaelis UR, Fleming I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol Ther 2006; 111:584-595. (Pubitemid 44160519)
4. Hillig T, Krustrup P, Fleming I, et al. Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans. J Physiol (Lond) 2003; 546:307-314. (Pubitemid 36104990)
5. Bellien J, Iacob M, Gutierrez L, et al. Crucial role of NO and endotheliumderived hyperpolarizing factor in human sustained conduit artery flowmediated dilatation. Hypertension 2006; 48:1088-1094. (Pubitemid 44772712)
6. Bellien J, Joannides R, Iacob M, et al. Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Am J Physiol Heart Circ Physiol 2006; 290:H1347-H1352.
7. Fischer D, Landmesser U, Spiekermann S, et al. Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure. Eur J Heart Fail 2007; 9:770-775. (Pubitemid 47212832)
8. Ozkor MA, Murrow JR, Rahman AM, et al. Endothelium-derived hyperpolarizing factor determines resting and stimulated forearm vasodilator tone in health and in disease. Circulation 2011; 123:2244-2253.
9. Virdis A, Cetani F, Giannarelli C, et al. The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment. J Clin Endocrinol Metab 2010; 95:920-927.
10. Bauersachs J, Popp R, Hecker M, et al. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 1996; 94:3341-3347. (Pubitemid 26427507)
11. Fisslthaler B, Hinsch N, Chataigneau T, et al. Nifedipine increases cytochrome P4502C expression and EDHF-mediated responses in coronary arteries. Hypertension 2000; 36:270-275. (Pubitemid 30626999)
12. Fisslthaler B, Michaelis UR, Randriamboavonjy V, et al. Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. Biochim Biophys Acta 2003; 1619:332-339. (Pubitemid 36160611)
13. Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 2007; 292:C996-C1012. (Pubitemid 46442641)
14. Zordoky BNM, El-Kadi AOS. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Therapeut 2010; 125:446-463.
15. Yu BN, Luo CH, Wang D, et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 2004; 348:57-61. (Pubitemid 39209001)
16. Fleming I, Michaelis UR, Bredenkö tter D, et al. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 2001; 88:44-51. (Pubitemid 32064081)
17. Fichtlscherer S, Dimmeler S, Breuer S, et al. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 2004; 109:178-183. (Pubitemid 38114136)
18. Ma Y, Ni W, ZhuWet al. Association of genetic polymorphisms of CYP 2C19 with hypertension in a Chinese Han population. Blood Press 2011; 20:166-170.
19. Yang YN, Wang XL, Ma YT, et al. Association of interaction between smoking and CYP 2C19-3 polymorphism with coronary artery disease in a Uighur population. Clin App Thrombosis/Hemostasis 2010; 16:579-583.
20. Teh LK, Zahri MK, Zakaria ZA, et al. Mutational analysis of CYP2C8 in hypertensive patients using denaturing high performance liquid chromatography. J Clin Pharm Therap 2010; 35:723-728.
21. Yu Z, Xu F, Huse LM, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000; 87:992-998.
22. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 2005; 289:F496-F503. (Pubitemid 41208461)
23. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009; 8:794-805.
24. Certikova Chabova V, Walkowska A, Kompanowska-Jezierska E, et al. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertensioninduced end-organ damage in Ren-2 transgenic rats. Clin Sci 2010; 118:617-632.
25. Ai D, Fu Y, Guo D, et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA 2007; 104:9018-9023. (Pubitemid 47175429)
26. Ai D, Pang W, Li N, et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci USA 2009; 106:564-569.
27. Simpkins AN, Rudic RD, Roy S, et al. Soluble epoxide hydrolase inhibition modulates vascular remodeling. Am J Physiol Heart Circ Physiol 2010; 298: H795-H806.
28. Revermann M, Schloss M, Barbosa-Sicard E, et al. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. Arterioscler Thromb Vasc Biol 2010; 30:909-914.
29. Hutchens MP, Nakano T, Dunlap J, et al. Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. Resuscitation 2008; 76:89-94. (Pubitemid 350235086)
30. Corenblum MJ, Wise VE, Georgi K, et al. Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat. Hypertension 2008; 51:567-573. (Pubitemid 351156449)
31. Gschwendtner A, Ripke S, Freilinger T, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans. Stroke 2008; 39:1593-1596.
32. Kullmann S, Binner P, Rackebrandt K, et al. Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention. BMC Cardiovasc Disord 2009; 9:48.
33. Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, et al. Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol 2003; 64:482-490. (Pubitemid 36910013)
34. Keserü B, Barbosa-Sicard E, Schermuly RT, et al. Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition. Cardiovasc Res 2010; 85:232-240.
35. Barbosa-Sicard E, Frö mel T, Keserü B, et al. Inhibition of the soluble epoxide hydrolase by tyrosine nitration. J Biol Chem 2009; 284:28156-28163.
36. Loot AE, Fleming I. Cytochrome P450-derived epoxyeicosatrienoic acids and pulmonary hypertension: central role of transient receptor potential (TRP) C6 channels. J Cardiovasc Pharmacol 2011; 57:140-147.
37. Pokreisz P, Fleming I, Kiss L, et al. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 2006; 47:762-770. (Pubitemid 43740249)
38. Keserü B, Barbosa-Sicard E, Popp R, et al. Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. FASEB J 2008; 22:4306-4315.
39. Weissmann N, Dietrich A, Fuchs B, et al. Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc Natl Acad Sci USA 2006; 103:19093-19098. (Pubitemid 350002833)
40. Kiss L, Schutte H, Padberg W, et al. Epoxyeicosatrienoates are the dominant eicosanoids in human lungs upon microbial challenge. Eur Resp J 2010; 36:1088-1098.
41. Konkel A, SchunckWH. Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta 2011; 1814:210-222.
42. Serhan CN. The resolution of inflammation: the devil in the flask and in the details. FASEB J 2011; 25:1441-1448.
43. Diaz Encarnacion MM, Warner GM, Cheng J, et al. n-3 Fatty acids block TNFa-stimulated MCP-1 expression in rat mesangial cells. Am J Physiol Renal Physiol 2011; 300:F1142-F1151.
44. Kitamura K, Shibata R, Tsuji Y, et al. Eicosapentaenoic acid prevents atrial fibrillation associated with heart failure in a rabbit model. Am J Physiol-Heart Circ Physiol 2011; 300:H1814-H1821.
45. Finzi AA, Latini R, Barlera S, et al. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: a substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. Am Heart J 2011; 161:338-343.
46. Arnold C, Markovic M, Blossey K, et al. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of v-3 fatty acids. J Biol Chem 2010; 285:32723-32733.
47. Egert S, Stehle P. Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Curr Opin Clin Nutr Metab Care 2011; 14:121-131.
48. Madden J, Williams CM, Calder PC et al. The impact of common gene variants on the response of biomarkers of cardiovascular disease (CVD) risk to increased fish oil fatty acids intakes. Annu Rev Nutr 2011; 31:203-234.
49. Bazan HA, Lu Y, Thoppil D, et al. Diminished omega-3 fatty acids are associated with carotid plaques from neurologically symptomatic patients: implications for carotid interventions. Vascul Pharmacol 2009; 51:331-336.
50. Jung O, Jansen F, Mieth A, et al. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS ONE 2010; 5:e11979.
51. Liu JY, Yang J, Inceoglu B, et al. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 2010; 79:880-887.